Related Experiment Video

Updated: Mar 9, 2026

Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5
05:45

Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5

Published on: April 26, 2019

14.2K

Acute Diarrhoea in Children: Determination of Duration Using a Combined Bismuth Hydroxide Gel and Oral Rehydration

Adriana Oviedo1, Mirna Díaz2, María Laura Valenzuela3

  • 1Sección de Gastroenterología, Servicio de Pediatría, Hospital Nacional Alejandro Posadas, 1684 El Palomar, Buenos Aires, Argentina. adriana-oviedo215@hotmail.com.

Children (Basel, Switzerland)
|December 24, 2016
PubMed

Insights

Colloidal bismuth hydroxide gel (CBHG) combined with oral rehydration salts (ORS) significantly reduced acute diarrhoea (AD) duration in children. This combined treatment nearly halved recovery time compared to ORS alone, improving outcomes for childhood AD.

Area of Science:

  • Pediatrics
  • Gastroenterology
  • Infectious Diseases

Background:

  • Acute diarrhoea (AD) in children remains a significant cause of morbidity despite oral rehydration salt (ORS) treatment reducing mortality.
  • Effective strategies to decrease the duration and severity of AD are needed.

Purpose of the Study:

  • To evaluate the efficacy of combined colloidal bismuth hydroxide gel (CBHG) and ORS treatment in reducing the duration of acute diarrhoea in children compared to ORS alone.

Main Methods:

  • A double-blind, randomized prospective study was conducted with pediatric patients (1-12 years) diagnosed with AD.
  • Participants were assigned to either an ORS and CBHG treatment group or a control group receiving ORS plus placebo.
  • Statistical analysis included Chi-squared and Mann-Whitney tests, Cox proportional hazards model, and Kaplan-Meier estimator.

Main Results:

  • The mean duration of AD was significantly shorter in the CBHG + ORS group (25.5 hours) compared to the placebo group (41.5 hours) (p=0.015).
  • The average number of stools was also lower in the treated group (4.8) versus the control group (8.2) (p=0.032).
  • Fewer children in the CBHG + ORS group had persistent AD after 24 hours.

Conclusions:

  • Combined CBHG and ORS treatment significantly reduces the duration and severity of acute diarrhoea in children.
  • This therapeutic approach offers a more rapid resolution of AD symptoms compared to ORS therapy alone.
  • CBHG represents a promising adjunct to ORS for managing acute paediatric diarrhoea.

Keywords:
acute diarrhoeabismuth hydroxide gelhydration salts

More Related Videos

Bile Salt-induced Biofilm Formation in Enteric Pathogens: Techniques for Identification and Quantification10:05

Bile Salt-induced Biofilm Formation in Enteric Pathogens: Techniques for Identification and Quantification

Published on: May 6, 2018

13.4K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.3K

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
515
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
689
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
821
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
595
Lower GI Series: Barium Enema01:23

Lower GI Series: Barium Enema

A Barium Enema, or a lower GI series, is a specialized radiographic examination designed to visualize the lower gastrointestinal tract, specifically the colon and rectum. This procedure is instrumental in diagnosing various conditions such as colorectal cancer, polyps, diverticulosis, and inflammatory bowel disease.
Procedure Details
The examination begins by inserting a lubricated rectal tube into the patient's rectum to administer a radiopaque barium solution. The barium flow is carefully...
2.1K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
1.0K